Clinical Trial Update: Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment

View source ↗

Summary

A completed observational trial update from Bayer describing an Italian study to quantify how many non-valvular atrial fibrillation patients stopped or changed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-valvular Atrial Fibrillation

Drugs mentioned

• Xarelto (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Non-valvular Atrial Fibrillation | Status: COMPLETED